Citi keeps Buy rating on Protagonist Therapeutics
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Citi reiterated its Buy rating on Protagonist Therapeutics with a USD 182.00 price target. The call follows a strong second quarter in 2026, when the company reported USD 213.48 million in revenue and USD 162.85 million in net income, a sharp improvement from the prior year.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.